Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy With Velcade (Bortezomib), Doxorubicin, and Dexamethasone (PAD) as Therapy for Patients With Relapsed or Refractory Multiple Myeloma

NCT00814541 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT00814541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00814541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy With Velcade (Bortezomib), Doxorubicin, and Dexamethasone (PAD) as Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
December 31, 2012
Enrollment
53 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm